Docket Number:12A-950206、12A-950206B
Inventor:Yuan-Tsong Chen, Wen-Hung Chung, Shuen-Iu Hung
IP Status:Issued US7,718,378、US8,377,436、TWI333978
Abstract:
This invention encompasses the discovery of a specific cytotoxic protein (granulysin) that can be used as a rapid and non-invasive way to establish the diagnosis of SJS/TEN and GVHD and to monitor the disease progression, and act as a therapeutic target to develop a novel therapy for SJS/TEN and GVHD.
Fields of Application:
Current therapy of cytotoxic T cells mediated diseases, such as SJS/TEN, or GVHD, is not efficacious. None of the published data on individual or combined treatment efficacies of SJS/TEN and GVHD is sufficiently strong to suggest a definitive treatment. The striking expression of a cytotoxic protein (granulysin) described in the Invention can be used in rapid diagnosis, monitoring disease progression, and as a therapeutic target to develop an effective therapy for SJS/TEN and GVHD.
Advantages when compared to the existing technologies:
- Measurement of granulysin in blood and blister fluid can provide a rapid and non-invasive way of diagnosing SJS/TEN and GVHD, instead of current use of skin biopsy which is invasive and time consuming.
- None of the current method/technology has been clinically useful for monitoring the progression of these diseases. Granulysis could be used a therapeutic target to develop a more effective therapy for SJS/TEN and GVHD.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
IP Status:Issued US7718378、US8377436、TWI333978
